All 3 patients demonstrated increased 89Zr-Df-IAB22M2C uptake in tumor lesions after initiation of immunotherapy, indicating the presence of CD8+ tumor–infiltrating leukocytes, and correlated with subsequent benefit from immunotherapy. This evidence concerns the gene CD8A and neoplasm.